Food and Drug Administration for any medical, cosmetic, or investigational use
Patients with type two diabetes can take semaglutide (Wegovy, Ozempic, Rybelsus) to lose weight, lower blood sugar levels and reduce the risk of major cardiovascular events such as heart attacks and strokes
That said, these effects are not yet well established clinically, and more research is needed to determine whether they are directly caused by the medication or influenced by factors such as weight loss, metabolic changes, or individual physiology
I have not personally seen most of the other symptoms highlighted in the study in a consistent or clinically significant way
Semaglutide may be especially familiar to patients because of its established role in obesity and diabetes care